DC05F01

DRUG2 trials

Sponsors

Heronova Pharmaceuticals

Conditions

Ovarian CancerSmall Cell Lung CancerSolid Tumors

Phase 1

A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors

CompletedNCT06873542

Heronova PharmaceuticalsSolid Tumors

Start: 2022-07-08End: 2024-01-02Updated: 2025-03-12

A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

RecruitingNCT06873555

Heronova PharmaceuticalsOvarian Cancer, Small Cell Lung Cancer, Solid Tumors

Start: 2024-09-11End: 2027-12-01Target: 60Updated: 2026-09-16